Ekaterina Vladimirovna Makarova
Ekaterina Vladimirovna Makarova has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Ivan S. Krysanov
Moscow State University of Food Production
23 shared publications - Denis Vladimirovich Kurkin
Russian University of Medicine. 2. Volgograd State Medical University
12 shared publications - Victoria Yu. Ermakova
Russian Biotechnological University ; Institute of Clinical and Economic Expertise and Pharmacoeconomics ; Sechenov University
12 shared publications - Larisa A. Marchenkova
Национальный медицинский исследовательский центр реабилитации и курортологии
10 shared publications - Elena M. Styazhkina
National Medical Research Center for Rehabilitation and Balneology
6 shared publications - V. S. Krysanova
BIOTECH University
6 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 23 (4) , 391-399
Clinical and Economic Effectiveness of an Amino Acid Formula with a Synbiotic Component in infants with Cow’s milk Protein Allergy
Background . The use of amino acid formulas (AAF) in severe cow’s milk protein allergy (CMPA) is a generally accepted standard of care for infants. A promising strategy for CMPA control is modulation of the gut microbiota through a synbiotic complex. The high cost of AAF reduces family compliance and limits the effectiveness of therapy, while the lack of clinical and economic evaluations of AAF use in the Russian Federation does not allow for an objective assessment of the reduction in the overall disease burden. The aim of the study was to conduct a pharmacoeconomic assessment of the use of amino acid-based therapeutic formulas in infants with CMPA in the Russian healthcare system. Materials and methods . The study included AAF with and without a synbiotic complex, registered for use in the Russian Federation as of the end of 2025 in infants from birth with severe CMPA: Neocate Syneo, Alfare Amino, Nutrilak Premium Amino. A cost-effectiveness analysis and one-way sensitivity analysis were performed. Results . Annual costs of diet therapy amounted to 414,624 rubles for Neocate Syneo, 394,848 rubles for Alfare Amino, and 331,968 rubles for Nutrilak Premium Amino. At the same time, the use of Neocate Syneo was associated with a significant reduction in the cost of treating complications: 20,698.19 rubles versus 49,261.56 rubles with conventional AAF (58% savings). Total direct medical costs with Neocate Syneo amounted to 435,322.19 rubles per year, which was higher than with Nutrilak Premium Amino (+54,092.63 rubles) and comparable to the costs of Alfare Amino (–8,787.37 rubles). The cost-effectiveness analysis showed that the cost of one case of complete symptom resolution was minimal with Neocate Syneo (640,179.70 rubles), which is 34.5–43.8% more cost-effective compared to other AAF. The advantage of Neocate Syneo was maintained even with an increase in the product price of up to 52% or a decrease in clinical effectiveness of 34%. Conclusion . The use of Neocate Syneo in infants with CMPA is economically feasible and has a clinical advantage over AAF without a synbiotic component. Neocate Syneo contributes to improved clinical outcomes, reduced risk of complications, improved quality of life and cost optimization in the Russian healthcare system.
- 1 October 2026
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 23 (4) , 391-399
Open AccessClinical and Economic Effectiveness of an Amino Acid Formula with a Synbiotic Component in infants with Cow’s milk Protein Allergy
Background . The use of amino acid formulas (AAF) in severe cow’s milk protein allergy (CMPA) is a generally accepted standard of care for infants. A promising strategy for CMPA control is modulation of the gut microbiota through a synbiotic complex. The high cost of AAF reduces family compliance and limits the effectiveness of therapy, while the lack of clinical and economic evaluations of AAF use in the Russian Federation does not allow for an objective assessment of the reduction in the overall disease burden. The aim of the study was to conduct a pharmacoeconomic assessment of the use of amino acid-based therapeutic formulas in infants with CMPA in the Russian healthcare system. Materials and methods . The study included AAF with and without a synbiotic complex, registered for use in the Russian Federation as of the end of 2025 in infants from birth with severe CMPA: Neocate Syneo, Alfare Amino, Nutrilak Premium Amino. A cost-effectiveness analysis and one-way sensitivity analysis were performed. Results . Annual costs of diet therapy amounted to 414,624 rubles for Neocate Syneo, 394,848 rubles for Alfare Amino, and 331,968 rubles for Nutrilak Premium Amino. At the same time, the use of Neocate Syneo was associated with a significant reduction in the cost of treating complications: 20,698.19 rubles versus 49,261.56 rubles with conventional AAF (58% savings). Total direct medical costs with Neocate Syneo amounted to 435,322.19 rubles per year, which was higher than with Nutrilak Premium Amino (+54,092.63 rubles) and comparable to the costs of Alfare Amino (–8,787.37 rubles). The cost-effectiveness analysis showed that the cost of one case of complete symptom resolution was minimal with Neocate Syneo (640,179.70 rubles), which is 34.5–43.8% more cost-effective compared to other AAF. The advantage of Neocate Syneo was maintained even with an increase in the product price of up to 52% or a decrease in clinical effectiveness of 34%. Conclusion . The use of Neocate Syneo in infants with CMPA is economically feasible and has a clinical advantage over AAF without a synbiotic component. Neocate Syneo contributes to improved clinical outcomes, reduced risk of complications, improved quality of life and cost optimization in the Russian healthcare system.
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 483-492
Clinical and economic assessment of an extended release lanreotide formulation (Somatuline® Autogel®) in patients with gastrointestinal neuroendocrine tumors
Objective: To conduct a comparative pharmacoeconomic assessment of the use of extended release formulations of lanreotide and octreotide in adult patients (over 18 years of age) with gastrointestinal neuroendocrine tumors (GI NETs) in the Russian healthcare system in 2025. Material and methods. A comparative analysis of clinical trial data, including randomized controlled trials and retrospective cohort studies, was conducted on the efficacy and safety profiles of lanreotide and octreotide. The focus was on overall survival, progressionfree survival, and the incidence of adverse events. Next the study employed the methods involving the calculation of the costeffectiveness ratio (CER) and the incremental cost-effectiveness ratio (ICER), as well as sensitivity analysis. Economic parameters (costs, CER, ICER) are presented both in absolute values (rubles) and as relative measures (%). Results . The average costs of drug therapy with lanreotide for 10 years per patient comprised 7,213,219.59 rubles, compared to 4,279,437.69 rubles for a course of extended release octreotide (a difference of 40.67%). At the same time, the costs of treating adverse events were lower for lanreotide compared to octreotide, equaling 24,604.01 and 59,203.81 rubles, respectively (a difference of 58.4%). Direct medical costs for a 10-year course of lanreotide therapy in one patient with GI NETs were 7,237,823.60 rubles, compared to 4,338,641.50 rubles for a course of octreotide, with the difference comprising 2,899,182.10 rubles (40.06%). When calculating CER, the cost of 1 month of extended life with lanreotide therapy was 63,825.60 rubles, compared to 48,046.97 rubles using octreotide (a difference of 32,83%). When recalculated to annual costs, the cost of 1 year of extended life with lanreotide therapy was 765,907.26 rubles, compared to 576,563.65 rubles using octreotide (a difference of 24.73%). ICER for lanreotide was 1,506,068.62 rubles per year, which is within the limits of justified economic costs, being significantly lower than the willingness to pay for the Russian Federation (about 3,350,000 rubles per year). Results of a one-way sensitivity analysis showed that the benefit of lanreotide is achieved with a 25% increase in the price of octreotide or a 33% increase in overall survival with lanreotide. Conclusion. The use of lanreotide in adult patients with GI NETs is both a clinically justified and economically feasible choice in the context of Russian healthcare.
- 22 January 2026
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (4) , 483-492
Clinical and economic assessment of an extended release lanreotide formulation (Somatuline® Autogel®) in patients with gastrointestinal neuroendocrine tumors
Objective: To conduct a comparative pharmacoeconomic assessment of the use of extended release formulations of lanreotide and octreotide in adult patients (over 18 years of age) with gastrointestinal neuroendocrine tumors (GI NETs) in the Russian healthcare system in 2025. Material and methods. A comparative analysis of clinical trial data, including randomized controlled trials and retrospective cohort studies, was conducted on the efficacy and safety profiles of lanreotide and octreotide. The focus was on overall survival, progressionfree survival, and the incidence of adverse events. Next the study employed the methods involving the calculation of the costeffectiveness ratio (CER) and the incremental cost-effectiveness ratio (ICER), as well as sensitivity analysis. Economic parameters (costs, CER, ICER) are presented both in absolute values (rubles) and as relative measures (%). Results . The average costs of drug therapy with lanreotide for 10 years per patient comprised 7,213,219.59 rubles, compared to 4,279,437.69 rubles for a course of extended release octreotide (a difference of 40.67%). At the same time, the costs of treating adverse events were lower for lanreotide compared to octreotide, equaling 24,604.01 and 59,203.81 rubles, respectively (a difference of 58.4%). Direct medical costs for a 10-year course of lanreotide therapy in one patient with GI NETs were 7,237,823.60 rubles, compared to 4,338,641.50 rubles for a course of octreotide, with the difference comprising 2,899,182.10 rubles (40.06%). When calculating CER, the cost of 1 month of extended life with lanreotide therapy was 63,825.60 rubles, compared to 48,046.97 rubles using octreotide (a difference of 32,83%). When recalculated to annual costs, the cost of 1 year of extended life with lanreotide therapy was 765,907.26 rubles, compared to 576,563.65 rubles using octreotide (a difference of 24.73%). ICER for lanreotide was 1,506,068.62 rubles per year, which is within the limits of justified economic costs, being significantly lower than the willingness to pay for the Russian Federation (about 3,350,000 rubles per year). Results of a one-way sensitivity analysis showed that the benefit of lanreotide is achieved with a 25% increase in the price of octreotide or a 33% increase in overall survival with lanreotide. Conclusion. The use of lanreotide in adult patients with GI NETs is both a clinically justified and economically feasible choice in the context of Russian healthcare.
- Open Access
- 18 December 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (4) , 467-478
Drug Provision for Patients with Cutaneous Melanoma in Outpatient Settings: Regional Experience
INTRODUCTION. Despite its relatively low share in the structure of oncological incidence, cutaneous melanoma (CM) is one of the most cost-intensive nosologies. The emerging new combination treatment regimens require regular pharmacoeconomic monitoring. AIM. This study aimed to evaluate the current structure, dynamics, and costs of drug therapy in Moscow region over 2020–2022 based on pharmacoepidemiological and pharmacoeconomic analysis of subsidised drug provision in order to identify key regional trends. MATERIALS AND METHODS . Primary depersonalised data were obtained from patient medical records in the Unified Medical Information and Analytical System (EMIAS). The analysis included total number of patients and their clinical profile (gender, age, diagnosis code); for the drugs, international non-proprietary name, dosage form, dosage, number of packages sold, and total cost was analysed. Cost analysis considered both total cost and structure in terms of selected international non-proprietary names. An additional analysis was conducted for a three-year period. RESULTS. Data from 1,522 patients diagnosed with ICD-10 C43.0–43.9 were examined (465 patients in 2020, 526 patients in 2021, and 531 patients in 2022). Over the study period, the number of patients increased by 14%, with gender structure gradually changing and the ratio of men decreasing from 44.3% to 39.9%. Two-thirds of the patients received drug therapy for the primary disease. Total outpatient costs ranged from 407.6 million rubles in 2020 to 615.3 million rubles in 2022. CM share of drug therapy averaged 98% of the total cost. Over 2020–2022, the highest patient coverage, number of packages, and cost level was attributed to dabrafenib+trametinib and vemurafenib+cobimetinib combinations. They accounted for an average of 85% of all patients and almost 99% of all costs. Over the 3-year period, there was a twofold cost increase for dabrafenib and trametinib, with a comparable twofold cost decrease for vemurafenib and cobimetinib. CONCLUSIONS . Pharmacotherapy structure, dynamics, and cost has been evaluated in CM patients of Moscow region over 2020–2022. The obtained data can be used to optimise pharmacotherapy of CM patients at the regional level by widely introducing both clinical and pharmacoeconomic evaluation principles of treatment approaches.
- 18 December 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (4) , 467-478
Open AccessDrug Provision for Patients with Cutaneous Melanoma in Outpatient Settings: Regional Experience
INTRODUCTION. Despite its relatively low share in the structure of oncological incidence, cutaneous melanoma (CM) is one of the most cost-intensive nosologies. The emerging new combination treatment regimens require regular pharmacoeconomic monitoring. AIM. This study aimed to evaluate the current structure, dynamics, and costs of drug therapy in Moscow region over 2020–2022 based on pharmacoepidemiological and pharmacoeconomic analysis of subsidised drug provision in order to identify key regional trends. MATERIALS AND METHODS . Primary depersonalised data were obtained from patient medical records in the Unified Medical Information and Analytical System (EMIAS). The analysis included total number of patients and their clinical profile (gender, age, diagnosis code); for the drugs, international non-proprietary name, dosage form, dosage, number of packages sold, and total cost was analysed. Cost analysis considered both total cost and structure in terms of selected international non-proprietary names. An additional analysis was conducted for a three-year period. RESULTS. Data from 1,522 patients diagnosed with ICD-10 C43.0–43.9 were examined (465 patients in 2020, 526 patients in 2021, and 531 patients in 2022). Over the study period, the number of patients increased by 14%, with gender structure gradually changing and the ratio of men decreasing from 44.3% to 39.9%. Two-thirds of the patients received drug therapy for the primary disease. Total outpatient costs ranged from 407.6 million rubles in 2020 to 615.3 million rubles in 2022. CM share of drug therapy averaged 98% of the total cost. Over 2020–2022, the highest patient coverage, number of packages, and cost level was attributed to dabrafenib+trametinib and vemurafenib+cobimetinib combinations. They accounted for an average of 85% of all patients and almost 99% of all costs. Over the 3-year period, there was a twofold cost increase for dabrafenib and trametinib, with a comparable twofold cost decrease for vemurafenib and cobimetinib. CONCLUSIONS . Pharmacotherapy structure, dynamics, and cost has been evaluated in CM patients of Moscow region over 2020–2022. The obtained data can be used to optimise pharmacotherapy of CM patients at the regional level by widely introducing both clinical and pharmacoeconomic evaluation principles of treatment approaches.
- Open Access
- 12 December 2025
- Published by ECO-Vector LLC (Publications) in Neurology Bulletin
- Vol. LVII (4) , 392-404
Modifiable risk factors for social maladjustment in individuals with gender identity disorder
BACKGROUND: Gender identity disorder includes a spectrum of conditions united by subjective distress—gender dysphoria syndrome—which adversely affects quality of life. The degree of social adjustment in individuals with gender identity disorder depends on baseline personality characteristics, the microsocial environment, and the effects of heterogeneous negative factors that vary in intensity and duration. AIM: This work aimed to identify modifiable factors affecting social adjustment and quality of life in patients with gender identity disorder. METHODS: A retrospective analysis was conducted of the medical records (n = 951) of patients who presented with complaints of gender dysphoria between 2014 and 2022. RESULTS: The most significant risk factors for social maladjustment were lack of support from close relatives; exposure to bullying at school; comorbid mental disorders; untimely or unreliable information about gender identity disorder; lack of effective assistance at the initial consultation for gender identity disorder; absence of external congruence with psychological gender; and social isolation. CONCLUSION: The findings indicate the need to develop personalized support strategies for patients with gender identity disorder of any origin, in accordance with legally established regulations. Such strategies may improve social adjustment at the individual and family levels, as well as in educational and workplace settings; reduce distress and social losses; and help unlock the economic potential of this young and physically healthy subgroup.
- 12 December 2025
- Published by ECO-Vector LLC (Publications) in Neurology Bulletin
- Vol. LVII (4) , 392-404
Open AccessModifiable risk factors for social maladjustment in individuals with gender identity disorder
BACKGROUND: Gender identity disorder includes a spectrum of conditions united by subjective distress—gender dysphoria syndrome—which adversely affects quality of life. The degree of social adjustment in individuals with gender identity disorder depends on baseline personality characteristics, the microsocial environment, and the effects of heterogeneous negative factors that vary in intensity and duration. AIM: This work aimed to identify modifiable factors affecting social adjustment and quality of life in patients with gender identity disorder. METHODS: A retrospective analysis was conducted of the medical records (n = 951) of patients who presented with complaints of gender dysphoria between 2014 and 2022. RESULTS: The most significant risk factors for social maladjustment were lack of support from close relatives; exposure to bullying at school; comorbid mental disorders; untimely or unreliable information about gender identity disorder; lack of effective assistance at the initial consultation for gender identity disorder; absence of external congruence with psychological gender; and social isolation. CONCLUSION: The findings indicate the need to develop personalized support strategies for patients with gender identity disorder of any origin, in accordance with legally established regulations. Such strategies may improve social adjustment at the individual and family levels, as well as in educational and workplace settings; reduce distress and social losses; and help unlock the economic potential of this young and physically healthy subgroup.
- Open Access
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 17-34
Regional experience in drug provision for patients with metastatic melanoma: a retrospective analysis of government procurement in Moscow region
Objective. To conduct a pharmacoepidemiologic and pharmacoeconomic analysis of government procurement of drugs for the treatment of metastatic melanoma (MM) in Moscow region during 2020–2022, assessing the compliance of real clinical practice with current recommendations and identifying opportunities to optimize drug provision for patients. Materials and methods. A retrospective pharmacoepidemiologic analysis of data on government procurement of key drugs used in the treatment of metastatic MM for the period 2020–2022 in Moscow region was performed, followed by a cost analysis. The analysis included 17 INNs: vemurafenib, vinblastine, dabrafenib, dacarbazine, imatinib, interferon alfa-2b, ipilimumab, carboplatin, cobimetinib, lomustine, nivolumab, paclitaxel, pembrolizumab, prolgolimab, temozolomide, trametinib, and cisplatin. The number of customers, trade names, dosage forms and packaging, number of packages purchased, cost per package, and total costs were analyzed. The average cost per 1 mg of active substance was separately evaluated over time. The results were processed using MS Excel 2019 and presented as absolute values and percentages. Results. Data from the procurement information system (https://zakupki.gov.ru) for 2020–2022 were analyzed, covering 1,831 government procurements of 17 INNs used for MM treatment in Moscow region healthcare facilities (622 in 2020, 686 in 2021, 523 in 2022). Total expenditure for the 17 INNs amounted to 4.8 billion rubles for the entire 2020–2022 period (1.3 billion in 2020, 1.8 billion in 2021, 1.7 billion rubles in 2022), with an increase in expenditure of more than 30 %. The cost structure was dominated by 3 INNs throughout the analyzed period — dabrafenib, nivolumab, and pembrolizumab, accounting for an average of 76.5 % of all expenses. During 2020–2022, pembrolizumab was the absolute leader (accounting for 39.2 % of purchases in 2020, 33.3 % in 2021, and 35.2 % in 2022), with cost growth of 1.2 times. Regarding the average cost per 1 mg of active substance, the most expensive MM treatments were: ipilimumab, trametinib, pembrolizumab, prolgolimab, and nivolumab. Over the 3-year period, among these INNs, only ipilimumab showed an increase in the average cost per 1 mg (+18.6 %), while prolgolimab showed a significant decrease (–17.2 %). When comparing different healthcare settings, there is a clear trend toward decreasing numbers of patients receiving oral targeted therapies in inpatient settings, while in outpatient settings the number of patients significantly increases, especially evident for the combination of dabrafenib and trametinib. Conclusions. Our study is the first example of a comprehensive pharmacoepidemiologic and pharmacoeconomic analysis covering various aspects of drug provision for patients with metastatic MM — government procurement, provision within preferential drug supply programs, and specialized medical care in hospital settings. The research results create an information base for making clinically and economically sound healthcare decisions, which can be used in developing regional oncology service programs, planning drug procurement, and improving the drug supply system for patients with metastatic MM.
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 17-34
Open AccessRegional experience in drug provision for patients with metastatic melanoma: a retrospective analysis of government procurement in Moscow region
Objective. To conduct a pharmacoepidemiologic and pharmacoeconomic analysis of government procurement of drugs for the treatment of metastatic melanoma (MM) in Moscow region during 2020–2022, assessing the compliance of real clinical practice with current recommendations and identifying opportunities to optimize drug provision for patients. Materials and methods. A retrospective pharmacoepidemiologic analysis of data on government procurement of key drugs used in the treatment of metastatic MM for the period 2020–2022 in Moscow region was performed, followed by a cost analysis. The analysis included 17 INNs: vemurafenib, vinblastine, dabrafenib, dacarbazine, imatinib, interferon alfa-2b, ipilimumab, carboplatin, cobimetinib, lomustine, nivolumab, paclitaxel, pembrolizumab, prolgolimab, temozolomide, trametinib, and cisplatin. The number of customers, trade names, dosage forms and packaging, number of packages purchased, cost per package, and total costs were analyzed. The average cost per 1 mg of active substance was separately evaluated over time. The results were processed using MS Excel 2019 and presented as absolute values and percentages. Results. Data from the procurement information system (https://zakupki.gov.ru) for 2020–2022 were analyzed, covering 1,831 government procurements of 17 INNs used for MM treatment in Moscow region healthcare facilities (622 in 2020, 686 in 2021, 523 in 2022). Total expenditure for the 17 INNs amounted to 4.8 billion rubles for the entire 2020–2022 period (1.3 billion in 2020, 1.8 billion in 2021, 1.7 billion rubles in 2022), with an increase in expenditure of more than 30 %. The cost structure was dominated by 3 INNs throughout the analyzed period — dabrafenib, nivolumab, and pembrolizumab, accounting for an average of 76.5 % of all expenses. During 2020–2022, pembrolizumab was the absolute leader (accounting for 39.2 % of purchases in 2020, 33.3 % in 2021, and 35.2 % in 2022), with cost growth of 1.2 times. Regarding the average cost per 1 mg of active substance, the most expensive MM treatments were: ipilimumab, trametinib, pembrolizumab, prolgolimab, and nivolumab. Over the 3-year period, among these INNs, only ipilimumab showed an increase in the average cost per 1 mg (+18.6 %), while prolgolimab showed a significant decrease (–17.2 %). When comparing different healthcare settings, there is a clear trend toward decreasing numbers of patients receiving oral targeted therapies in inpatient settings, while in outpatient settings the number of patients significantly increases, especially evident for the combination of dabrafenib and trametinib. Conclusions. Our study is the first example of a comprehensive pharmacoepidemiologic and pharmacoeconomic analysis covering various aspects of drug provision for patients with metastatic MM — government procurement, provision within preferential drug supply programs, and specialized medical care in hospital settings. The research results create an information base for making clinically and economically sound healthcare decisions, which can be used in developing regional oncology service programs, planning drug procurement, and improving the drug supply system for patients with metastatic MM.
- Open Access
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 4-16
Analysis of drug therapy for patients with metastatic melanoma of the skin using the example of the Moscow region
Objective. To conduct a pharmacoepidemiological and pharmacoeconomic analysis of specialized inpatient medical care provided to patients with metastatic melanoma (MM) in the Moscow Region during 2020–2022. Materials and methods. A retrospective pharmacoepidemiological analysis of specialized inpatient medical care provided to patients with MM in Moscow Region during 2020–2022 was performed, followed by a cost analysis. The study analyzed the total number of patients receiving various drug therapy regimens with their main clinical characteristics (gender, age, diagnosis code), the total number of hospitalizations considering their structure (inpatient/day hospital), the average number of hospitalizations per patient, and the average length of hospital stay. The cost analysis examined both total costs and their structure across different drug regimens. The results were processed using Microsoft Excel 2019 and are presented as absolute values and percentages (%). Results. This study examined 10,609 cases of specialized and primary specialized inpatient medical care provided to patients diagnosed with ICD-10 C43.0–43.9 in healthcare facilities of the Moscow Region from 2020 to 2022 (4,471 cases in 2020, 2,970 cases in 2021, and 3,168 cases in 2022). During the analysis period, the number of patients with MM receiving inpatient treatment decreased by 29 %, whereas the average number of hospitalizations per patient was 6.2 in 2020, 5.2 in 2021, and 6.3 in 2022. The hospitalization structure showed a trend toward decreasing the proportion of care provided in the 24-hour inpatient setting. The total costs of specialized medical care for patients with MM ranged from 1.8 billion rubles (2020) to 1.1 billion rubles (2022). In 2020, the three most demanded regimens by number of patients and hospitalizations were nivolumab, pembrolizumab, and dabrafenib + trametinib combination. This pattern persisted until 2021. In 2022, a shift in MM pharmacotherapy priorities was observed — alongside nivolumab and pembrolizumab regimens, prolgolimab became one of the most demanded treatments. These regimens were administered to more than 80 % of patients with MM at each time interval. Cost analysis revealed that in 2020, the same regimens that led in patient numbers also accounted for more than 95 % of total costs. In 2021 and 2022, the costliest regimens were those using nivolumab, pembrolizumab, and the combination of ipilimumab and nivolumab, accounting for more than 90 % of the costs. Drug therapy using pembrolizumab and nivolumab became the absolute leader both in patient numbers and costs throughout the entire analysis period, with nivolumab showing a gradual decrease in both patient numbers (1.7-fold) and cost levels (3.2-fold), while pembrolizumab showed the opposite trend —growth (1.5-fold and 1.9-fold, respectively). Conclusions. The results of this analysis can contribute to further improvement of the regional medical care system for patients with MM, thereby enhancing the quality and accessibility of modern and highly effective pharmacotherapy approaches.
- 28 October 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 3,p. 4-16
Open AccessAnalysis of drug therapy for patients with metastatic melanoma of the skin using the example of the Moscow region
Objective. To conduct a pharmacoepidemiological and pharmacoeconomic analysis of specialized inpatient medical care provided to patients with metastatic melanoma (MM) in the Moscow Region during 2020–2022. Materials and methods. A retrospective pharmacoepidemiological analysis of specialized inpatient medical care provided to patients with MM in Moscow Region during 2020–2022 was performed, followed by a cost analysis. The study analyzed the total number of patients receiving various drug therapy regimens with their main clinical characteristics (gender, age, diagnosis code), the total number of hospitalizations considering their structure (inpatient/day hospital), the average number of hospitalizations per patient, and the average length of hospital stay. The cost analysis examined both total costs and their structure across different drug regimens. The results were processed using Microsoft Excel 2019 and are presented as absolute values and percentages (%). Results. This study examined 10,609 cases of specialized and primary specialized inpatient medical care provided to patients diagnosed with ICD-10 C43.0–43.9 in healthcare facilities of the Moscow Region from 2020 to 2022 (4,471 cases in 2020, 2,970 cases in 2021, and 3,168 cases in 2022). During the analysis period, the number of patients with MM receiving inpatient treatment decreased by 29 %, whereas the average number of hospitalizations per patient was 6.2 in 2020, 5.2 in 2021, and 6.3 in 2022. The hospitalization structure showed a trend toward decreasing the proportion of care provided in the 24-hour inpatient setting. The total costs of specialized medical care for patients with MM ranged from 1.8 billion rubles (2020) to 1.1 billion rubles (2022). In 2020, the three most demanded regimens by number of patients and hospitalizations were nivolumab, pembrolizumab, and dabrafenib + trametinib combination. This pattern persisted until 2021. In 2022, a shift in MM pharmacotherapy priorities was observed — alongside nivolumab and pembrolizumab regimens, prolgolimab became one of the most demanded treatments. These regimens were administered to more than 80 % of patients with MM at each time interval. Cost analysis revealed that in 2020, the same regimens that led in patient numbers also accounted for more than 95 % of total costs. In 2021 and 2022, the costliest regimens were those using nivolumab, pembrolizumab, and the combination of ipilimumab and nivolumab, accounting for more than 90 % of the costs. Drug therapy using pembrolizumab and nivolumab became the absolute leader both in patient numbers and costs throughout the entire analysis period, with nivolumab showing a gradual decrease in both patient numbers (1.7-fold) and cost levels (3.2-fold), while pembrolizumab showed the opposite trend —growth (1.5-fold and 1.9-fold, respectively). Conclusions. The results of this analysis can contribute to further improvement of the regional medical care system for patients with MM, thereby enhancing the quality and accessibility of modern and highly effective pharmacotherapy approaches.
- 9 September 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 47 (3)
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Federation
Objective. Cost-effectiveness analysis of triptorelin and other luteinizing hormone releasing hormone (LHRH) agonists in the treatment of adults with prostate cancer. Material and methods. Cost-effectiveness analysis included costs of drugs and treatment of adverse events, budget impact analysis (BIA) and sensitivity analysis. Three LHRH agonists were selected (goserelin, leuprorelin, triptorelin). Results. The most efficient is triptorelin (35.870.01 rubles for a 9-month course of drug therapy). The highest cost is associated with leuprorelin therapy (54.945.51 rubles). Analysis of costs for AE relief showed that the lowest costs were associated with triptorelin (RUB 971.21), the highest — with goserelin (RUB 3.448.24). Thus, the highest total costs were associated with leuprorelin (RUB 57.857.15), the lowest — with triptorelin (RUB 36.841.22). The ratio of costs to probability of achieving serum testosterone<10 ng/dL after 9-month therapy was RUB 41.163.38 for triptorelin, RUB 69.456.36 for leuprorelin, and RUB 132.810.02 for goserelin. Triptorelin turned out to be strictly preferable compared to leuprorelin and goserelin due to higher efficiency and lower costs. According to BIA data, widespread triptorelin and leuprorelin therapy will decrease burden on healthcare system in the Russian Federation. Savings amount to 1 256 927.88 rubles for population of 1000 patients. Sensitivity analysis revealed that triptorelin retains its advantages even in deviations of baseline clinically significant parameters by ±10%. Conclusion. Compared to other LHRH agonists, triptorelin is cost-effective strategy for care in patients with prostate cancer in the Russian Federation.
- 9 September 2025
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 47 (3)
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Federation
Objective. Cost-effectiveness analysis of triptorelin and other luteinizing hormone releasing hormone (LHRH) agonists in the treatment of adults with prostate cancer. Material and methods. Cost-effectiveness analysis included costs of drugs and treatment of adverse events, budget impact analysis (BIA) and sensitivity analysis. Three LHRH agonists were selected (goserelin, leuprorelin, triptorelin). Results. The most efficient is triptorelin (35.870.01 rubles for a 9-month course of drug therapy). The highest cost is associated with leuprorelin therapy (54.945.51 rubles). Analysis of costs for AE relief showed that the lowest costs were associated with triptorelin (RUB 971.21), the highest — with goserelin (RUB 3.448.24). Thus, the highest total costs were associated with leuprorelin (RUB 57.857.15), the lowest — with triptorelin (RUB 36.841.22). The ratio of costs to probability of achieving serum testosterone<10 ng/dL after 9-month therapy was RUB 41.163.38 for triptorelin, RUB 69.456.36 for leuprorelin, and RUB 132.810.02 for goserelin. Triptorelin turned out to be strictly preferable compared to leuprorelin and goserelin due to higher efficiency and lower costs. According to BIA data, widespread triptorelin and leuprorelin therapy will decrease burden on healthcare system in the Russian Federation. Savings amount to 1 256 927.88 rubles for population of 1000 patients. Sensitivity analysis revealed that triptorelin retains its advantages even in deviations of baseline clinically significant parameters by ±10%. Conclusion. Compared to other LHRH agonists, triptorelin is cost-effective strategy for care in patients with prostate cancer in the Russian Federation.
- Open Access
- 23 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (2) , 84-97
Dynamics of turnover of sugar-lowering drugs in the retail segment of the pharmaceutical market from 2020 to 2024
A significant part of patients with diabetes purchase sugar-lowering drugs (SLDs) on their own in retail pharmacy chains, and the market trends they generate represent an urgent area for this study.The aim. To study the turnover of hypoglycemic drugs, including insulins, in the commercial sector of the pharmaceutical market of the Russian Federation (RF) for 2020–2024.Materials and methods. The data presented in this article is based on a periodic retail audit conducted by the biotech company IQVIA. The period of 5 years (2020–2024) was covered. Data collection covered 33,613 commercial pharmacies in all regions of the RF (about 43% of pharmacies).Results. In the period from 2020 to 2023, a relatively stable increase in the volume of SLDs purchases was revealed, with small fluctuations, while in 2024 a significant leap in consumption was recorded, both in quantitative (packages) and in value (rubles) terms. During the entire monitoring period, the total volume of SLDs and insulin purchases in the retail market segment increased by more than 1.2 times, from 41.98 million packages in 2020 to 51.70 million in 2024. At the same time, the total procurement budget (at wholesale prices) increased by more than 2 times — from 19.40 to 41.57 billion rubles. The average price per package has also increased significantly, from 462 rubles in 2020 to 923 rubles in 2024, an increase of 1.7 times, reflecting significant inflation in the commercial pharmaceutical sector. In general, the Russian pharmaceutical market offers all variants of modern innovative hypoglycemic drugs (dipeptidyl peptidase-4 inhibitors [iDPP4], sodium-glucose cotransporter 2 inhibitors [iSGLT2], glucagon-like peptide-1 receptor agonists [arGPP-1]), which, according to general trends, demonstrate a steady increase in turnover. Older and less effective sulfonylureas and their combinations with metformin still occupy a significant market share. arGPP-1 group showed the greatest growth in quantity (11 times) and value (5 times), mainly due to the entry of Russian semaglutide analogues into the market. Government measures and investments in import substitution have led to a significant increase in the share of Russian drugs in purchases. Despite the positive dynamics of Russian production, import substitution in the SLDs segment has not achieved complete success and accounts for less than half of the turnover of hypoglycemic drugs.Conclusion. The growth of SLDs consumption in the retail segment of the RF in 2020–2024 has been revealed, especially due to the innovative drugs arGPP-1 and iNGLT2. Despite maintaining the leading position of metformin, the consumption structure is shifting towards more expensive schemes. The increase in the total procurement budget and the average package price highlights the need to expand preferential security programs. Import substitution has increased significantly over the indicated period, however, the share of domestic drugs is still less than half of the turnover.
- 23 July 2025
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 13 (2) , 84-97
Open AccessDynamics of turnover of sugar-lowering drugs in the retail segment of the pharmaceutical market from 2020 to 2024
A significant part of patients with diabetes purchase sugar-lowering drugs (SLDs) on their own in retail pharmacy chains, and the market trends they generate represent an urgent area for this study.The aim. To study the turnover of hypoglycemic drugs, including insulins, in the commercial sector of the pharmaceutical market of the Russian Federation (RF) for 2020–2024.Materials and methods. The data presented in this article is based on a periodic retail audit conducted by the biotech company IQVIA. The period of 5 years (2020–2024) was covered. Data collection covered 33,613 commercial pharmacies in all regions of the RF (about 43% of pharmacies).Results. In the period from 2020 to 2023, a relatively stable increase in the volume of SLDs purchases was revealed, with small fluctuations, while in 2024 a significant leap in consumption was recorded, both in quantitative (packages) and in value (rubles) terms. During the entire monitoring period, the total volume of SLDs and insulin purchases in the retail market segment increased by more than 1.2 times, from 41.98 million packages in 2020 to 51.70 million in 2024. At the same time, the total procurement budget (at wholesale prices) increased by more than 2 times — from 19.40 to 41.57 billion rubles. The average price per package has also increased significantly, from 462 rubles in 2020 to 923 rubles in 2024, an increase of 1.7 times, reflecting significant inflation in the commercial pharmaceutical sector. In general, the Russian pharmaceutical market offers all variants of modern innovative hypoglycemic drugs (dipeptidyl peptidase-4 inhibitors [iDPP4], sodium-glucose cotransporter 2 inhibitors [iSGLT2], glucagon-like peptide-1 receptor agonists [arGPP-1]), which, according to general trends, demonstrate a steady increase in turnover. Older and less effective sulfonylureas and their combinations with metformin still occupy a significant market share. arGPP-1 group showed the greatest growth in quantity (11 times) and value (5 times), mainly due to the entry of Russian semaglutide analogues into the market. Government measures and investments in import substitution have led to a significant increase in the share of Russian drugs in purchases. Despite the positive dynamics of Russian production, import substitution in the SLDs segment has not achieved complete success and accounts for less than half of the turnover of hypoglycemic drugs.Conclusion. The growth of SLDs consumption in the retail segment of the RF in 2020–2024 has been revealed, especially due to the innovative drugs arGPP-1 and iNGLT2. Despite maintaining the leading position of metformin, the consumption structure is shifting towards more expensive schemes. The increase in the total procurement budget and the average package price highlights the need to expand preferential security programs. Import substitution has increased significantly over the indicated period, however, the share of domestic drugs is still less than half of the turnover.
- Open Access
- 19 July 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 34-45
Mosunetuzumab budget impact analysis in patients with recurrent or refractory follicular lymphoma
Aim. This study aimed to analyze the budget impact of mosunetuzumab use in patients with relapsed or refractory follicular lymphoma in the third and subsequent lines of therapy. Materials and methods. Budget impact analysis, sensitivity analysis. Results. The target population size was 340 people. Analysis of the costs of drug therapy for the third and subsequent lines demonstrated a wide range of costs: the maximum costs are associated with the use of mosunetuzumab (RUB 6,296,060.33, 8 cycles and RUB 11,906,411.12, 17 cycles), and the minimum costs are associated with the use of the GDP regimen without rituximab (RUB 31,390.80). The total costs for 1 year of modeling the current practice for all types of therapy amounted to RUB 891,446,565.79. In current practice, the main share of costs is attributed to the drug duvelisib (47.4 %), followed by the regimen ibrutinib+/-R (25.1 %) and R-B (6.1 %). More than 70 % of the current practice costs are spent on drugs that do not have an official indication for use. The total cost of 1 year of modeling amounted to RUB 693,639,708.26. Over the specified modeling period, the main share of costs was attributed to the following regimens: ibrutinib+/-R (32.3 %) and mosunetuzumab monotherapy (27.2 %). Budget impact analysis demonstrated that the use of mosunetuzumab will save 22.2 % or RUB 197,806,857.54 over 1 year and will allow for additional treatment with mosunetuzumab to 31 new patients. Sensitivity analysis of the budget impact analysis results demonstrated that the model is sustainable to changes in all initial parameters, even within the proposed option of transferring all patients from duvelisib to mosunetuzumab monotherapy will lead to a savings in current costs (2.9 %). Conclusions. The use of mosunetuzumab as a 3rd and subsequent line therapy in adult patients with relapsed or refractory follicular lymphoma is an economically feasible approach within the Russian healthcare framework.
- 19 July 2025
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 34-45
Open AccessMosunetuzumab budget impact analysis in patients with recurrent or refractory follicular lymphoma
Aim. This study aimed to analyze the budget impact of mosunetuzumab use in patients with relapsed or refractory follicular lymphoma in the third and subsequent lines of therapy. Materials and methods. Budget impact analysis, sensitivity analysis. Results. The target population size was 340 people. Analysis of the costs of drug therapy for the third and subsequent lines demonstrated a wide range of costs: the maximum costs are associated with the use of mosunetuzumab (RUB 6,296,060.33, 8 cycles and RUB 11,906,411.12, 17 cycles), and the minimum costs are associated with the use of the GDP regimen without rituximab (RUB 31,390.80). The total costs for 1 year of modeling the current practice for all types of therapy amounted to RUB 891,446,565.79. In current practice, the main share of costs is attributed to the drug duvelisib (47.4 %), followed by the regimen ibrutinib+/-R (25.1 %) and R-B (6.1 %). More than 70 % of the current practice costs are spent on drugs that do not have an official indication for use. The total cost of 1 year of modeling amounted to RUB 693,639,708.26. Over the specified modeling period, the main share of costs was attributed to the following regimens: ibrutinib+/-R (32.3 %) and mosunetuzumab monotherapy (27.2 %). Budget impact analysis demonstrated that the use of mosunetuzumab will save 22.2 % or RUB 197,806,857.54 over 1 year and will allow for additional treatment with mosunetuzumab to 31 new patients. Sensitivity analysis of the budget impact analysis results demonstrated that the model is sustainable to changes in all initial parameters, even within the proposed option of transferring all patients from duvelisib to mosunetuzumab monotherapy will lead to a savings in current costs (2.9 %). Conclusions. The use of mosunetuzumab as a 3rd and subsequent line therapy in adult patients with relapsed or refractory follicular lymphoma is an economically feasible approach within the Russian healthcare framework.
- Open Access
- 2 May 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (1) , 22-31
Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly
Background. Pharmacoeconomic aspects of somatostatin analogues remain an important topic for discussion. Despite the higher cost of lanreotide compared to octreotide, the former may have an advantage in terms of administration convenience and high efficacy.Objective: to carry out a cost-effectiveness analysis (CEA) of the use of lanreotide and prolonged-release octreotide in adult patients with acromegaly.Material and methods. A cost model for the treatment of acromegaly patients during the period of 2.5 years was developed, accounting for direct medical costs for drugs and surgical intervention. A pharmacoeconomic study by the CEA method and a sensitivity analysis of the model were performed.Results. In real clinical practice of acromegaly treatment, lanreotide enables a more effective remission compared to prolonged-release octreotide (51% vs 24%) under a comparable safety profile. The direct medical costs for a 2.5-year course of lanreotide amounted to 1,466,669.49 rubles per patient with acromegaly compared to 908,272.53 rubles for a course of prolonged-release octreotide. Considering the difference in the amount of 558,096.79 rubles, the course of lanreotide was found to be 25% more expensive. According to CEA results, the cost of achieving remission in 1 patient with acromegaly with lanreotide and prolonged-release octreotide was equal to 2,415,036.25 and 3,676,115.43 rubles, respectively. Therefore, over the period of 2.5 years, the cost saving amounted to 1,261,079.17 rubles (52%). The sensitivity analysis demonstrated the robustness of the initial model against an increase in the price of lanreotide up to 64%, an increase in the frequency of surgery in patients receiving lanreotide up to 302%, and a decrease in the frequency of remissions in patients receiving lanreotide up to 35%.Conclusion. The use of lanreotide in adult patients with acromegaly is a clinically and cost-effective approach in the context of the Russian healthcare system.
- 2 May 2025
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 18 (1) , 22-31
Open AccessPharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly
Background. Pharmacoeconomic aspects of somatostatin analogues remain an important topic for discussion. Despite the higher cost of lanreotide compared to octreotide, the former may have an advantage in terms of administration convenience and high efficacy.Objective: to carry out a cost-effectiveness analysis (CEA) of the use of lanreotide and prolonged-release octreotide in adult patients with acromegaly.Material and methods. A cost model for the treatment of acromegaly patients during the period of 2.5 years was developed, accounting for direct medical costs for drugs and surgical intervention. A pharmacoeconomic study by the CEA method and a sensitivity analysis of the model were performed.Results. In real clinical practice of acromegaly treatment, lanreotide enables a more effective remission compared to prolonged-release octreotide (51% vs 24%) under a comparable safety profile. The direct medical costs for a 2.5-year course of lanreotide amounted to 1,466,669.49 rubles per patient with acromegaly compared to 908,272.53 rubles for a course of prolonged-release octreotide. Considering the difference in the amount of 558,096.79 rubles, the course of lanreotide was found to be 25% more expensive. According to CEA results, the cost of achieving remission in 1 patient with acromegaly with lanreotide and prolonged-release octreotide was equal to 2,415,036.25 and 3,676,115.43 rubles, respectively. Therefore, over the period of 2.5 years, the cost saving amounted to 1,261,079.17 rubles (52%). The sensitivity analysis demonstrated the robustness of the initial model against an increase in the price of lanreotide up to 64%, an increase in the frequency of surgery in patients receiving lanreotide up to 302%, and a decrease in the frequency of remissions in patients receiving lanreotide up to 35%.Conclusion. The use of lanreotide in adult patients with acromegaly is a clinically and cost-effective approach in the context of the Russian healthcare system.